



Guerbet signs an agreement with Fuji Pharma to market its range of contrast media in Japan

Villepinte, July 31, 2015

Guerbet (GBT) announces an agreement with Fuji Pharma Co., Ltd, a leading provider of contrast media to distribute and promote its range of contrast media for MRI, X-Ray imaging and interventional radiology in Japan to be effective on October 2nd 2015.

This offering in Japan includes three contrast media. One for MRI imaging: Magnescope® (distributed outside of Japan under the brand name Dotarem®, leading contrast agent in Europe), one for X-Ray imaging contrast media: Hexabrix® 320, one for interventional radiology: Lipiodol®.

"In line with Fuji's ambition to strengthen their line of branded pharmaceuticals, this agreement will enable Guerbet to continue its growth strategy in a key Asian market, where radiology - and interventional radiology in particular - have significant potential for development, based on the increase in medical needs", said Steven Bleyl, President and Representative Director at Guerbet Japan.

Japan is a major strategic market for contrast media (€650 million for X-Ray and MRI combined). With a population of 127 million and 8,500 hospitals it has a very extensive installed base of medical equipment, more than double the installed base in Europe.

Press release

About Guerbet

Guerbet is a pioneer in the contrast agent field, with nearly 90 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on NYSE Euronext Paris (Segment B – Mid Caps) and generated revenue of €409 million in 2014. It had a total workforce of 1,461 employees at December 31, 2014.

For more information about **Guerbet**, please go to www.guerbet.com

About Fuji Pharma

Fuji specializes in the fields of woman healthcare, imaging contrast medium and biosimilar product, and particularly has strength in injectables products manufactured in the most advanced production lines in its Toyama works and OLIC (Thailand) Co., Ltd (Ayutaya, Thailand). In the imaging contrast medium fields, particularly for CT/X ray, Fuji has a 25.8% share in the Japanese market. Fuji lists in Tokyo Stock Exchange Market (first section), annual sales turnover (consolidated) is JPY 29.2 billion in September 2014 and has employees 1,467.

For more information about **Fuji Pharma** please go to www.fuji-pharma.jp.

Forward-looking statements

This press release may contain forward-looking statements based on current assumptions and forecasts made by Guerbet Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performances of the company and the estimates given here. These factors include those discussed in Guerbet's public reports which are available on the Guerbet website at www.guerbet.com. The company assumes no liability whatsoever to update these forward-looking-statements or to conform them to future events or developments.

Contacts

Media relations:

Guerbet

Anne-Laure Delasalle
Communications Director

+ 33 (0)1 45 91 50 03

anne-laure.delasalle@guerbet-group.com

Agence PRPA

Guillaume de Chamisso

+ 33 (0)1 46 99 69 69

+ 33 (0)1 77 35 60 99 / + 33 (0)6 28 79 00 61

guillaume.dechamisso@prpa.fr